<!DOCTYPE html>
<html lang="en-US">
<head>
<!-- Original URL: http://www.aimsci.com/ros/html/?page_id=1377
Date Downloaded: 12/25/2019 3:40:07 PM !-->
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
	<meta charset="UTF-8" />
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
	<link rel="pingback" href="http://www.aimsci.com/ros/html/xmlrpc.php" />

	<script type="text/javascript">
		document.documentElement.className = 'js';
	</script>

	<script>var et_site_url='index.html';var et_post_id='1377';function et_core_page_resource_fallback(a,b){"undefined"===typeof b&&(b=a.sheet.cssRules&&0===a.sheet.cssRules.length);b&&(a.onerror=null,a.onload=null,a.href?a.href=et_site_url+"/?et_core_page_resource="+a.id+et_post_id:a.src&&(a.src=et_site_url+"/?et_core_page_resource="+a.id+et_post_id))}
</script><title>2017; 4(10):251–265 | ss_site_title</title>
<link rel='dns-prefetch' href='//fonts.googleapis.com' />
<link rel='dns-prefetch' href='//s.w.org' />
<link rel="alternate" type="application/rss+xml" title="ss_site_title &raquo; Feed" href="_c0b1fbb3" />
<link rel="alternate" type="application/rss+xml" title="ss_site_title &raquo; Comments Feed" href="_387b1518" />
		<script type="text/javascript">
			window._wpemojiSettings = {"baseUrl":"https:\/\/s.w.org\/images\/core\/emoji\/11\/72x72\/","ext":".png","svgUrl":"https:\/\/s.w.org\/images\/core\/emoji\/11\/svg\/","svgExt":".svg","source":{"concatemoji":"wp-includes/js/wp-emoji-release.min_e0220a6d.js"}};
			!function(a,b,c){function d(a,b){var c=String.fromCharCode;l.clearRect(0,0,k.width,k.height),l.fillText(c.apply(this,a),0,0);var d=k.toDataURL();l.clearRect(0,0,k.width,k.height),l.fillText(c.apply(this,b),0,0);var e=k.toDataURL();return d===e}function e(a){var b;if(!l||!l.fillText)return!1;switch(l.textBaseline="top",l.font="600 32px Arial",a){case"flag":return!(b=d([55356,56826,55356,56819],[55356,56826,8203,55356,56819]))&&(b=d([55356,57332,56128,56423,56128,56418,56128,56421,56128,56430,56128,56423,56128,56447],[55356,57332,8203,56128,56423,8203,56128,56418,8203,56128,56421,8203,56128,56430,8203,56128,56423,8203,56128,56447]),!b);case"emoji":return b=d([55358,56760,9792,65039],[55358,56760,8203,9792,65039]),!b}return!1}function f(a){var c=b.createElement("script");c.src=a,c.defer=c.type="text/javascript",b.getElementsByTagName("head")[0].appendChild(c)}var g,h,i,j,k=b.createElement("canvas"),l=k.getContext&&k.getContext("2d");for(j=Array("flag","emoji"),c.supports={everything:!0,everythingExceptFlag:!0},i=0;i<j.length;i++)c.supports[j[i]]=e(j[i]),c.supports.everything=c.supports.everything&&c.supports[j[i]],"flag"!==j[i]&&(c.supports.everythingExceptFlag=c.supports.everythingExceptFlag&&c.supports[j[i]]);c.supports.everythingExceptFlag=c.supports.everythingExceptFlag&&!c.supports.flag,c.DOMReady=!1,c.readyCallback=function(){c.DOMReady=!0},c.supports.everything||(h=function(){c.readyCallback()},b.addEventListener?(b.addEventListener("DOMContentLoaded",h,!1),a.addEventListener("load",h,!1)):(a.attachEvent("onload",h),b.attachEvent("onreadystatechange",function(){"complete"===b.readyState&&c.readyCallback()})),g=c.source||{},g.concatemoji?f(g.concatemoji):g.wpemoji&&g.twemoji&&(f(g.twemoji),f(g.wpemoji)))}(window,document,window._wpemojiSettings);
		</script>
		<meta content="Divi v.3.19.7" name="generator" /><style type="text/css">
img.wp-smiley,
img.emoji {
	display: inline !important;
	border: none !important;
	box-shadow: none !important;
	height: 1em !important;
	width: 1em !important;
	margin: 0 .07em !important;
	vertical-align: -0.1em !important;
	background: none !important;
	padding: 0 !important;
}
</style>
<link rel='stylesheet' id='wp-block-library-css' href='wp-includes/css/dist/block-library/style.min_e0220a6d.css' type='text/css' media='all' />
<link rel='stylesheet' id='divi-fonts-css' href='../../../fonts.googleapis.com/css_6b0aa6b1.css' type='text/css' media='all' />
<link rel='stylesheet' id='divi-style-css' href='wp-content/themes/Divi/style_1e2ae7de.css' type='text/css' media='all' />
<link rel='stylesheet' id='dashicons-css' href='wp-includes/css/dashicons.min_e0220a6d.css' type='text/css' media='all' />
<script type='text/javascript' src='wp-includes/js/jquery/jquery_85ec8bd8.js'></script>
<script type='text/javascript' src='wp-includes/js/jquery/jquery-migrate.min_e021f9e6.js'></script>
<link rel='https://api.w.org/' href='index_ba315afa.php' />
<link rel="EditURI" type="application/rsd+xml" title="RSD" href="xmlrpc_b9b66041.php" />
<link rel="wlwmanifest" type="application/wlwmanifest+xml" href="wp-includes/wlwmanifest.xml" /> 
<meta name="generator" content="WordPress 5.0.8" />
<link rel="canonical" href="_afcec184.html" />
<link rel='shortlink' href='_afcec184.html' />
<link rel="alternate" type="application/json+oembed" href="index_c8e25ccd.php" />
<link rel="alternate" type="text/xml+oembed" href="index_d0562916.php" />
<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" /><link rel="stylesheet" id="et-divi-customizer-global-cached-inline-styles" href="wp-content/cache/et/global/et-divi-customizer-global-15766348400072.min.css" onerror="et_core_page_resource_fallback(this, true)" onload="et_core_page_resource_fallback(this)" /></head>
<body class="page-template-default page page-id-1377 et_pb_button_helper_class et_fixed_nav et_show_nav et_cover_background et_pb_gutter windows et_pb_gutters3 et_primary_nav_dropdown_animation_fade et_secondary_nav_dropdown_animation_fade et_pb_footer_columns4 et_header_style_left et_right_sidebar et_divi_theme et-db et_minified_js et_minified_css">
	<div id="page-container">

	
	
			<header id="main-header" data-height-onload="66">
			<div class="container clearfix et_menu_container">
							<div class="logo_container">
					<span class="logo_helper"></span>
					<a href="index.html">
						<img src="wp-content/uploads/2016/03/ROS-blue-square.png" alt="ss_site_title" id="logo" data-height-percentage="54" />
					</a>
				</div>
							<div id="et-top-navigation" data-height="66" data-fixed-height="40">
											<nav id="top-menu-nav">
						<ul id="top-menu" class="nav"><li id="menu-item-1503" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1503"><a href="_ad6635bd.html">2016</a>
<ul class="sub-menu">
	<li id="menu-item-168" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-168"><a href="_2e83399d.html">2016 Vol 1 No 1</a>
	<ul class="sub-menu">
		<li id="menu-item-155" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-155"><a href="_468cdbca.html">2016; 1(1):1–8</a></li>
		<li id="menu-item-154" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-154"><a href="_468cdbcc.html">2016; 1(1):9–21</a></li>
		<li id="menu-item-153" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-153"><a href="_468cdbbe.html">2016; 1(1):22–37</a></li>
		<li id="menu-item-152" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-152"><a href="_73d222cd.html">2016; 1(1):38–52</a></li>
		<li id="menu-item-151" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-151"><a href="_73d222cf.html">2016; 1(1):53–58</a></li>
		<li id="menu-item-150" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-150"><a href="_73d222d1.html">2016; 1(1):59–64</a></li>
		<li id="menu-item-149" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-149"><a href="_73d222d3.html">2016; 1(1):65–80</a></li>
		<li id="menu-item-165" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-165"><a href="_2e833998.html">2016; 1(1):81–98</a></li>
	</ul>
</li>
	<li id="menu-item-208" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-208"><a href="_d12aae32.html">2016 Vol 1 No 2</a>
	<ul class="sub-menu">
		<li id="menu-item-207" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-207"><a href="_d12aae34.html">2016; 1(2):99–109</a></li>
		<li id="menu-item-206" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-206"><a href="_d12aae36.html">2016; 1(2):110–116</a></li>
		<li id="menu-item-205" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-205"><a href="_d12aae38.html">2016; 1(2):117–130</a></li>
		<li id="menu-item-204" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-204"><a href="_d12aae2a.html">2016; 1(2):131–140</a></li>
		<li id="menu-item-203" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-203"><a href="_d3f8ab89.html">2016; 1(2):141–156</a></li>
		<li id="menu-item-202" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-202"><a href="_d3f8ab8b.html">2016; 1(2):157–164</a></li>
		<li id="menu-item-201" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-201"><a href="_d3f8ab8d.html">2016; 1(2):165–177</a></li>
	</ul>
</li>
	<li id="menu-item-289" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-289"><a href="_d3f8aba4.html">2016 Vol 1 No 3</a>
	<ul class="sub-menu">
		<li id="menu-item-273" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-273"><a href="_d12aae53.html">2016; 1(3):178–188</a></li>
		<li id="menu-item-277" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-277"><a href="_d12aae57.html">2016; 1(3):189–198</a></li>
		<li id="menu-item-280" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-280"><a href="_d12aae4c.html">2016; 1(3):199–206</a></li>
		<li id="menu-item-517" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-517"><a href="_8bdbc57e.html">2016; 1(3):207–215</a></li>
		<li id="menu-item-286" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-286"><a href="_d3f8abaf.html">2016; 1(3):216–227</a></li>
		<li id="menu-item-292" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-292"><a href="_76a02046.html">2016; 1(3):228–244</a></li>
	</ul>
</li>
	<li id="menu-item-587" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-587"><a href="_d3f8ac0b.html">2016 Vol 2 No 4</a>
	<ul class="sub-menu">
		<li id="menu-item-607" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-607"><a href="_e9345108.html">2016; 2(4):245–263</a></li>
		<li id="menu-item-576" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-576"><a href="_d12aaeb3.html">2016; 2(4):264–271</a></li>
		<li id="menu-item-677" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-677"><a href="_2e833a37.html">2016; 2(4):272–289</a></li>
		<li id="menu-item-651" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-651"><a href="_73d2236e.html">2016; 2(4):290–297</a></li>
		<li id="menu-item-641" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-641"><a href="_468cdc66.html">2016; 2(4):298–307</a></li>
		<li id="menu-item-692" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-692"><a href="_d3f8ac2e.html">2016; 2(4):308–314</a></li>
	</ul>
</li>
	<li id="menu-item-735" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-735"><a href="_468cdc8b.html">2016 Vol 2 No 5</a>
	<ul class="sub-menu">
		<li id="menu-item-741" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-741"><a href="_468cdc85.html">2016; 2(5):315–324</a></li>
		<li id="menu-item-751" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-751"><a href="_73d2238b.html">2016; 2(5):325–338</a></li>
		<li id="menu-item-766" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-766"><a href="_2e833a59.html">2016; 2(5):339–354</a></li>
		<li id="menu-item-781" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-781"><a href="_d12aaef1.html">2016; 2(5):355–360</a></li>
		<li id="menu-item-807" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-807"><a href="_e9344f3d.html">2016; 2(5):361–370</a></li>
		<li id="menu-item-713" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-713"><a href="_8bdbc5c3.html">2016; 2(5):371–387</a></li>
	</ul>
</li>
	<li id="menu-item-844" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-844"><a href="_73d221a8.html">2016 Vol 2 No 6</a>
	<ul class="sub-menu">
		<li id="menu-item-868" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-868"><a href="_2e833876.html">2016; 2(6):388–395</a></li>
		<li id="menu-item-879" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-879"><a href="_d12aad11.html">2016; 2(6):396–403</a></li>
		<li id="menu-item-914" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-914"><a href="_8bdbc3f6.html">2016; 2(6):404–416</a></li>
		<li id="menu-item-886" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-886"><a href="_d3f8aa66.html">2016; 2(6):417–420</a></li>
		<li id="menu-item-834" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-834"><a href="_468cdaa1.html">2016; 2(6):421–431</a></li>
		<li id="menu-item-897" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-897"><a href="_76a01f00.html">2016; 2(6):432–439</a></li>
	</ul>
</li>
</ul>
</li>
<li id="menu-item-1507" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-ancestor current_page_ancestor menu-item-has-children menu-item-1507"><a href="_22c86351.html">2017</a>
<ul class="sub-menu">
	<li id="menu-item-940" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-940"><a href="_468cdac6.html">2017 Vol 3 No 7</a>
	<ul class="sub-menu">
		<li id="menu-item-932" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-932"><a href="_a3e5662c.html">2017; 3(7):1–11</a></li>
		<li id="menu-item-1007" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1007"><a href="_5141f038.html">2017; 3(7):12–25</a></li>
		<li id="menu-item-1017" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1017"><a href="_5141f039.html">2017; 3(7):26–37</a></li>
		<li id="menu-item-1030" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1030"><a href="_ec1045b.html">2017; 3(7):38–46</a></li>
		<li id="menu-item-944" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-944"><a href="_73d221c7.html">2017; 3(7):47–65</a></li>
		<li id="menu-item-1039" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1039"><a href="_bf30705.html">2017; 3(7):66–80</a></li>
	</ul>
</li>
	<li id="menu-item-1074" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1074"><a href="_deadc002.html">2017 Vol 3 No 8</a>
	<ul class="sub-menu">
		<li id="menu-item-1069" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1069"><a href="_bf30708.html">2017; 3(8):81–95</a></li>
		<li id="menu-item-1132" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1132"><a href="_71b58a6f.html">2017; 3(8):96–110</a></li>
		<li id="menu-item-1128" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1128"><a href="_b70473a4.html">2017; 3(8):111–120</a></li>
		<li id="menu-item-1112" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1112"><a href="_71b58a6d.html">2017; 3(8):121–126</a></li>
		<li id="menu-item-1098" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1098"><a href="_694b9260.html">2017; 3(8):127–134</a></li>
		<li id="menu-item-1084" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1084"><a href="_deadbff3.html">2017; 3(8):135–147</a></li>
	</ul>
</li>
	<li id="menu-item-1174" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1174"><a href="_2c66a13d.html">2017 Vol 3 No 9</a>
	<ul class="sub-menu">
		<li id="menu-item-1194" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1194"><a href="_2c66a12f.html">2017; 3(9):148–183</a></li>
		<li id="menu-item-1286" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1286"><a href="_1cc6f704.html">2017; 3(9):184–188</a></li>
		<li id="menu-item-1177" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1177"><a href="_cf0e15d8.html">2017; 3(9):189–196</a></li>
		<li id="menu-item-1186" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1186"><a href="_fc535cd0.html">2017; 3(9):197–207</a></li>
		<li id="menu-item-1299" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1299"><a href="_a764c971.html">2017; 3(9):208–217</a></li>
		<li id="menu-item-1312" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1312"><a href="_82897a77.html">2017; 3(9):218–236</a></li>
	</ul>
</li>
	<li id="menu-item-1347" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-ancestor current-menu-parent current_page_parent current_page_ancestor menu-item-has-children menu-item-1347"><a href="_6a7fd84b.html">2017 Vol 4 No 10</a>
	<ul class="sub-menu">
		<li id="menu-item-1352" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1352"><a href="_82897a7b.html">2017; 4(10):237–250</a></li>
		<li id="menu-item-1379" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-1377 current_page_item menu-item-1379"><a href="_afcec184.html">2017; 4(10):251–265</a></li>
		<li id="menu-item-1400" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1400"><a href="_6d4dd597.html">2017; 4(10):266–274</a></li>
		<li id="menu-item-1360" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1360"><a href="_6d4dd5a3.html">2017; 4(10):275–283</a></li>
		<li id="menu-item-1371" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1371"><a href="_caa66109.html">2017; 4(10):284–289</a></li>
		<li id="menu-item-1388" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1388"><a href="_6a7fd83f.html">2017; 4(10):290–297</a></li>
	</ul>
</li>
	<li id="menu-item-1423" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1423"><a href="_a4fc3dba.html">2017 Vol 4 No 11</a>
	<ul class="sub-menu">
		<li id="menu-item-1419" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1419"><a href="_d50f8217.html">2017; 4(11):298–302</a></li>
		<li id="menu-item-1429" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1429"><a href="_d50f8218.html">2017; 4(11):303–319</a></li>
		<li id="menu-item-1438" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1438"><a href="_32680d7e.html">2017; 4(11):320–335</a></li>
		<li id="menu-item-1458" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1458"><a href="_32680d80.html">2017; 4(11):336–350</a></li>
		<li id="menu-item-1478" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1478"><a href="_32680d82.html">2017; 4(11):351–361</a></li>
		<li id="menu-item-1490" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1490"><a href="_ed19243d.html">2017; 4(11):362–371</a></li>
	</ul>
</li>
	<li id="menu-item-1530" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1530"><a href="_3ad20582.html">2017 Vol 4 No 12</a>
	<ul class="sub-menu">
		<li id="menu-item-1591" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1591"><a href="_982a90dd.html">2017; 4(12):372–381</a></li>
		<li id="menu-item-1551" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1551"><a href="_982a90e9.html">2017; 4(12):382–388</a></li>
		<li id="menu-item-1562" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1562"><a href="_500daa5e.html">2017; 4(12):389–417</a></li>
		<li id="menu-item-1538" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1538"><a href="_8020eeb9.html">2017; 4(12):418–433</a></li>
		<li id="menu-item-1605" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1605"><a href="_fb1f16f8.html">2017; 4(12):434–440</a></li>
		<li id="menu-item-1526" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1526"><a href="_c56fd7ee.html">2017; 4(12):441–444</a></li>
	</ul>
</li>
</ul>
</li>
<li id="menu-item-1679" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1679"><a href="_70814493.html">2018</a>
<ul class="sub-menu">
	<li id="menu-item-1667" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1667"><a href="_888ae6c1.html">2018 Vol 5 No 13</a>
	<ul class="sub-menu">
		<li id="menu-item-1671" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1671"><a href="_a09488f0.html">2018; 5(13):1–14</a></li>
		<li id="menu-item-1757" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1757"><a href="_339c5360.html">2018; 5(13):15–34</a></li>
		<li id="menu-item-1742" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1742"><a href="_a8fe80f2.html">2018; 5(13):35–45</a></li>
		<li id="menu-item-1683" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1683"><a href="_b5d02dba.html">2018; 5(13):46–55</a></li>
		<li id="menu-item-1703" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1703"><a href="_be3a25c7.html">2018; 5(13):56–67</a></li>
		<li id="menu-item-1714" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1714"><a href="_a6308399.html">2018; 5(13):68–77</a></li>
	</ul>
</li>
	<li id="menu-item-1810" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1810"><a href="_7c880e31.html">2018 Vol 5 No 14</a>
	<ul class="sub-menu">
		<li id="menu-item-1814" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1814"><a href="_21fd8024.html">2018; 5(14):78–85</a></li>
		<li id="menu-item-1835" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1835"><a href="_c4a4f4c1.html">2018; 5(14):86–106</a></li>
		<li id="menu-item-1860" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1860"><a href="_7c880e36.html">2018; 5(14):107–117</a></li>
		<li id="menu-item-1802" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1802"><a href="_a8fe80e8.html">2018; 5(14):118–125</a></li>
		<li id="menu-item-1847" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1847"><a href="_9491b064.html">2018; 5(14):126–133</a></li>
		<li id="menu-item-1870" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1870"><a href="_7c880e37.html">2018; 5(14):134–144</a></li>
	</ul>
</li>
	<li id="menu-item-1902" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1902"><a href="_b5054a94.html">2018 Vol 5 No 15</a>
	<ul class="sub-menu">
		<li id="menu-item-1934" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1934"><a href="_6fb66161.html">2018; 5(15):145–158</a></li>
		<li id="menu-item-1956" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1956"><a href="_3fa31d05.html">2018; 5(15):159–166</a></li>
		<li id="menu-item-1898" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1898"><a href="_ac9b5288.html">2018; 5(15):167–175</a></li>
		<li id="menu-item-1911" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1911"><a href="_27997ad1.html">2018; 5(15):176–198</a></li>
		<li id="menu-item-1924" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1924"><a href="_6fb66160.html">2018; 5(15):199–208</a></li>
		<li id="menu-item-1944" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1944"><a href="_6fb66162.html">2018; 5(15):209–219</a></li>
	</ul>
</li>
	<li id="menu-item-1993" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1993"><a href="_125dd5f2.html">2018 Vol 6 No 16</a>
	<ul class="sub-menu">
		<li id="menu-item-2036" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2036"><a href="_ae9a7bbd.html">2018; 6(16):220–247</a></li>
		<li id="menu-item-2007" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2007"><a href="_5141f05b.html">2018; 6(16):248–252</a></li>
		<li id="menu-item-1989" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1989"><a href="_fa5433c2.html">2018; 6(16):253–266</a></li>
		<li id="menu-item-2020" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2020"><a href="_ec1047b.html">2018; 6(16):267–275</a></li>
		<li id="menu-item-2046" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2046"><a href="_ae9a7bc4.html">2018; 6(16):276–288</a></li>
		<li id="menu-item-2056" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2056"><a href="_ae9a7bc3.html">2018; 6(16):289–298</a></li>
	</ul>
</li>
	<li id="menu-item-2086" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-2086"><a href="_ae9a7bb8.html">2018 Vol 6 No 17</a>
	<ul class="sub-menu">
		<li id="menu-item-2156" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2156"><a href="_89bf2cc1.html">2018; 6(17):299–310</a></li>
		<li id="menu-item-2082" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2082"><a href="_23fca94c.html">2018; 6(17):311–324</a></li>
		<li id="menu-item-2102" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2102"><a href="_71b58a8f.html">2018; 6(17):325–337</a></li>
		<li id="menu-item-2119" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2119"><a href="_145cff29.html">2018; 6(17):338–348</a></li>
		<li id="menu-item-2134" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2134"><a href="_2c66a156.html">2018; 6(17):349–362</a></li>
		<li id="menu-item-2177" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2177"><a href="_59abe861.html">2018; 6(17):363–370</a></li>
		<li id="menu-item-2169" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2169"><a href="_b70473c7.html">2018; 6(17):371–372</a></li>
	</ul>
</li>
	<li id="menu-item-2200" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-2200"><a href="_5c79e5ae.html">2018 Vol 6 No 18</a>
	<ul class="sub-menu">
		<li id="menu-item-2204" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2204"><a href="_7a1f8294.html">2018; 6(18):373–388</a></li>
		<li id="menu-item-2242" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2242"><a href="_34d09962.html">2018; 6(18):389–395</a></li>
		<li id="menu-item-2213" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2213"><a href="_d7780df8.html">2018; 6(18):396–405</a></li>
		<li id="menu-item-2226" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2226"><a href="_bf6e6bc8.html">2018; 6(18):406–413</a></li>
		<li id="menu-item-2257" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2257"><a href="_6215e068.html">2018; 6(18):414–427</a></li>
		<li id="menu-item-2278" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2278"><a href="_4bd5501.html">2018; 6(18):428–444</a></li>
	</ul>
</li>
</ul>
</li>
<li id="menu-item-2315" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-2315"><a href="_2530ef33.html">2019</a>
<ul class="sub-menu">
	<li id="menu-item-2311" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-2311"><a href="_6d4dd5c1.html">2019 Vol 7 No 19</a>
	<ul class="sub-menu">
		<li id="menu-item-2306" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2306"><a href="_d274d05.html">2019; 7(19):1–9</a></li>
		<li id="menu-item-2386" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2386"><a href="_d274cfd.html">2019; 7(19):10–20</a></li>
		<li id="menu-item-2321" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2321"><a href="_caa66125.html">2019; 7(19):21–29</a></li>
		<li id="menu-item-2338" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2338"><a href="_52763638.html">2019; 7(19):30–46</a></li>
		<li id="menu-item-2362" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2362"><a href="_82897a9b.html">2019; 7(19):47–54</a></li>
		<li id="menu-item-2372" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2372"><a href="_82897a9a.html">2019; 7(19):55–63</a></li>
	</ul>
</li>
	<li id="menu-item-2427" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-2427"><a href="_1a5e6b6d.html">2019 Vol 7 No 20</a>
	<ul class="sub-menu">
		<li id="menu-item-2770" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2770"><a href="_a63083be.html">2019; 7(20):64–77</a></li>
		<li id="menu-item-2653" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2653"><a href="_5877a27f.html">2019; 7(20):78–85</a></li>
		<li id="menu-item-2740" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2740"><a href="_cdd9d011.html">2019; 7(20):86–92</a></li>
		<li id="menu-item-2743" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2743"><a href="_5877a27e.html">2019; 7(20):93–105</a></li>
		<li id="menu-item-2895" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2895"><a href="_21fd8046.html">2019; 7(20):106–120</a></li>
		<li id="menu-item-2919" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2919"><a href="_c4a4f4e3.html">2019; 7(20):121–128</a></li>
	</ul>
</li>
	<li id="menu-item-2960" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-2960"><a href="_ca40ef92.html">2019 Vol 7 No 21</a>
	<ul class="sub-menu">
		<li id="menu-item-3026" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3026"><a href="_694b92a9.html">2019; 7(21):129–135</a></li>
		<li id="menu-item-3117" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3117"><a href="_c6a41e07.html">2019; 7(21):136–147</a></li>
		<li id="menu-item-3029" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3029"><a href="_fa5433e5.html">2019; 7(21):148–153</a></li>
		<li id="menu-item-3135" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3135"><a href="_59abe87d.html">2019; 7(21):154–160</a></li>
		<li id="menu-item-3047" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3047"><a href="_6fb66183.html">2019; 7(21):161–175</a></li>
		<li id="menu-item-3085" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3085"><a href="_c6a41e10.html">2019; 7(21):176–187</a></li>
	</ul>
</li>
	<li id="menu-item-3197" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3197"><a href="_59abe878.html">2019 Vol 8 No 22</a>
	<ul class="sub-menu">
		<li id="menu-item-3291" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3291"><a href="_4bd5522.html">2019; 8(22):188–195</a></li>
		<li id="menu-item-3234" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3234"><a href="_7a1f82b1.html">2019; 8(22):196–201</a></li>
		<li id="menu-item-3360" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3360"><a href="_c7d863ed.html">2019; 8(22):202–212</a></li>
		<li id="menu-item-3218" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3218"><a href="_b9d27134.html">2019; 8(22):213–221</a></li>
		<li id="menu-item-3270" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3270"><a href="_1cc6f752.html">2019; 8(22):222–230</a></li>
		<li id="menu-item-3330" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3330"><a href="_82897ab8.html">2019; 8(22):231–244</a></li>
	</ul>
</li>
	<li id="menu-item-3418" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3418"><a href="_32680dbe.html">2019 Vol 8 No 23</a>
	<ul class="sub-menu">
		<li id="menu-item-3451" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3451"><a href="_254c95d.html">2019; 8(23):245–257</a></li>
		<li id="menu-item-3500" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3500"><a href="_a4fc3df2.html">2019; 8(23):258–266</a></li>
		<li id="menu-item-3552" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3552"><a href="_3ad205c1.html">2019; 8(23):267–275</a></li>
		<li id="menu-item-3470" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3470"><a href="_77b6f6f8.html">2019; 8(23):276–286</a></li>
		<li id="menu-item-3536" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3536"><a href="_22c86393.html">2019; 8(23):287–296</a></li>
		<li id="menu-item-3579" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3579"><a href="_500daa9c.html">2019; 8(23):297–311</a></li>
	</ul>
</li>
	<li id="menu-item-3644" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3644"><a href="_5877a2a3.html">2019 Vol 8 No 24</a>
	<ul class="sub-menu">
		<li id="menu-item-3732" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3732"><a href="_60e19aa5.html">2019; 8(24):312–322</a></li>
		<li id="menu-item-3666" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3666"><a href="_cdd9d037.html">2019; 8(24):323–331</a></li>
		<li id="menu-item-3705" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3705"><a href="_b5d02e07.html">2019; 8(24):332–340</a></li>
		<li id="menu-item-3756" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3756"><a href="_d643c837.html">2019; 8(24):341–357</a></li>
		<li id="menu-item-3786" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3786"><a href="_78eb3cd5.html">2019; 8(24):358–371</a></li>
	</ul>
</li>
</ul>
</li>
<li id="menu-item-3889" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3889"><a href="_4f42c764.html">2020</a>
<ul class="sub-menu">
	<li id="menu-item-3863" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3863"><a href="_9f3de38.html">2020 Vol 9 No 25</a>
	<ul class="sub-menu">
		<li id="menu-item-3886" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3886"><a href="_9491b0a4.html">2020; 9(25):1–12</a></li>
		<li id="menu-item-3914" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3914"><a href="_9f3de2f.html">2020; 9(25):13–21</a></li>
		<li id="menu-item-4021" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4021"><a href="_27997b14.html">2020; 9(25):22–35</a></li>
		<li id="menu-item-4096" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4096"><a href="_694b92cd.html">2020; 9(25):36–47</a></li>
	</ul>
</li>
</ul>
</li>
</ul>						</nav>
					
					
					
										<div id="et_top_search">
						<span id="et_search_icon"></span>
					</div>
					
					<div id="et_mobile_nav_menu">
				<div class="mobile_nav closed">
					<span class="select_page">Select Page</span>
					<span class="mobile_menu_bar mobile_menu_bar_toggle"></span>
				</div>
			</div>				</div> <!-- #et-top-navigation -->
			</div> <!-- .container -->
			<div class="et_search_outer">
				<div class="container et_search_form_container">
					<form role="search" method="get" class="et-search-form" action="http://www.aimsci.com/ros/html/">
					<input type="search" class="et-search-field" placeholder="Search &hellip;" value="" name="s" title="Search for:" />					</form>
					<span class="et_close_search_field"></span>
				</div>
			</div>
		</header> <!-- #main-header -->
			<div id="et-main-area">
	
<div id="main-content">


	<div class="container">
		<div id="content-area" class="clearfix">
			<div id="left-area">


			
				<article id="post-1377" class="post-1377 page type-page status-publish hentry">

				
					<h1 class="entry-title main_title">2017; 4(10):251–265</h1>
				
				
					<div class="entry-content">
					<h1><span style="color: #808000;"><strong>REVIEW ARTICLES</strong></span></h1>
<h1><a href="../index.php/ros/article/view/95/207.html"><img class="alignright wp-image-231 " src="wp-content/uploads/2016/03/PDF-logo-blue-30.png" alt="PDF logo-blue 30" width="53" height="67" /></a></h1>
<p>&nbsp;</p>
<h2><strong>Reactive Oxygen Species Signaling in Cancer Development</strong></h2>
<p>&nbsp;</p>
<p><strong>Wei Mu and Ling-Zhi Liu</strong></p>
<p>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA</p>
<p>Correspondence: Ling-zhi.Liu@jefferson.edu (L.Z.L.)</p>
<p><em>Mu W and Liu LZ. Reactive Oxygen Species 4(10):251–265, 2017; ©2017 Cell Med Press</em></p>
<p><a href="../index.php/ros/article/view/95.html"><em>http://dx.doi.org/10.20455/ros.2017.843</em></a></p>
<p><em>(Received: March 31, 2017; Revised: April 17, 2017; Accepted: April 17, 2017)</em></p>
<p><strong>ABSTRACT</strong> <strong>|</strong> Cancer cells exist in chronic condition of metabolic oxidative stress compared to normal cells mainly due to inherent mitochondrial dysfunction and NADPH oxidases activation. DNA damage, mutation, and altered gene expression induced by reactive oxygen species (ROS) are all required participants in the process of carcinogenesis. The modification of gene expression by ROS has direct effects on cancer development such as tumor growth, survival, invasion and angiogenesis through the manipulation of signaling pathways, thus promoting metastasis. Meanwhile, some ROS-regulated miRNAs are also involved in mediating tumor progress. Although a precise mechanism of signal transduction remains to be elucidated, in this review we outline the probable role of these signaling cascades and ROS-regulated miRNAs in mediating tumor metastasis. Understanding of the molecular functions of ROS as one of key mediators in cancer development may provide widely opportunities for pharmacological intervention and anticancer therapy.</p>
<p><strong>KEYWORDS</strong> <strong>|</strong> Cancer development; miRNA; Reactive oxygen species; Signal transduction</p>
<p><strong>ABBREVIATIONS |</strong> AP-1, activating protein-1; DDR1, discoidin domain receptor 1; DNMT, DNA methyltransferase; ECM, extracellular matrix; EMT; epithelial-to-mesenchymal transition; ERK1/2, extracellular-regulated kinase ½; Ets, E twenty-six; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; FAK, focal adhesion kinase; GSH, glutathione; GST, glutathione S-transferase; HIF-1, hypoxia inducible factor-1; IKK, IκB kinase; IL, interleukin; JNK, c-Jun N-terminal kinase; 5-LOX, 5-lipoxygenase; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; MEKK, mitogen-activated protein kinase kinase kinase; MKP3, mitogen-activated protein kinase phosphatase 3; MMP, matrix metalloproteinase; NAC, N-acetyl-L-cysteine; NF-κB, nuclear factor κ-B; NIK, NF-κB-inducing kinase; PDGF, platelet-derived growth factor; PKC, protein kinase C; ROS, reactive oxygen species; RTK, receptor tyrosine kinase; SFK, Src family of protein tyrosine kinase; SOD, superoxide dismutase; TGFβ, transforming growth factor β; TLR, toll-like receptor; TIMP, tissue inhibitor of metalloproteinase; TNFα, tumor necrosis factor α; TRAF, TNF receptor-associated factor; VEGF, vascular endothelial growth factor</p>
<hr />
<p><strong> </strong><strong>CONTENTS</strong></p>
<p>1. Reactive Oxygen Species (ROS) in Cancer</p>
<p>2. The Signaling Cascades Induced by ROS in Promoting Cancer Development</p>
<p>2.1. Regulation of Src Kinases by ROS</p>
<p>2.2. Regulation of PI3K/AKT Pathway by ROS</p>
<p>2.3. Regulation of Mitogen-Activated Protein Kinases (MAPKs) Pathway by ROS</p>
<p>2.4. Regulation of Nuclear Factor κ-B (NF-κB) Pathway by ROS</p>
<p>3. The Interplay of ROS and microRNAs (miRNAs) in Tumor Metastasis</p>
<p>3.1. ROS-Upregulated miRNAs in Carcinogenesis and Cancer Development</p>
<p>3.2. ROS-Downregulated miRNAs in Carcinogenesis and Cancer Development</p>
<p>4. Summary</p>
<hr />
<p><strong>1. REACTIVE OXYGEN SPECIES (ROS)</strong> <strong>IN CANCER</strong></p>
<p>ROS are oxygen-derived small molecules that are produced as normal byproducts of cellular metabolism. ROS are generally categorized as free oxygen radicals and non-radicals. The free oxygen radicals contain one or more unpaired electrons in their outermost shell such as superoxide (O<sub>2</sub><strong>˙</strong>ˉ) and hydroxyl radical (OH<strong>˙</strong>). In contrast, non-radical ROS including hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), single oxygen (<sup>1</sup>O<sub>2</sub>) and ozone/trioxygen (O<sub>3</sub>) do not have unpaired electron. In aerobic organism, the balance of oxidation and antioxidation is mainly controlled by ROS level which is regulated via a wide variety of mechanisms such as superoxide dismutase (SOD), catalase, glutathione (GSH) and thioredoxin (TRX) [1, 2]. ROS generation is a cascade of reactions that begins with the production of superoxide [3]. Briefly, intracellular superoxide radicals are abundantly produced by electrons leaked from aerobic respiration at the inner membrane of the mitochondria [2, 4], or by the oxidation of NADPH by NADPH oxidase enzymes (NOX) in the cytosol [5, 6]. The majority of superoxide is rapidly dismutated to H<sub>2</sub>O<sub>2</sub> by superoxide dismutase 2 (SOD2) in the mitochondrial matrix, whereas some of the superoxide is converted to H<sub>2</sub>O<sub>2 </sub>by SOD1 in the cytosol. H<sub>2</sub>O<sub>2 </sub>is capable of oxidizing cysteine residues on proteins to initiate redox biology, or H<sub>2</sub>O<sub>2 </sub>may be converted to H<sub>2</sub>O by cellular antioxidants such as catalase, peroxiredoxins (PRx) and glutathione peroxidase (GPx). Other sources of ROS generation include peroxynitrite formation by the reaction of superoxide with nitric oxide, the peroxidase-catalyzed formation of hypochlorous acid from hydrogen peroxide, and the generation of hydroxyl radical from the metal cations (Fe<sup>2+</sup>)-catalyzed Fenton reaction [7, 8]. This process is highly reactive and can cause damage to cellular macromolecules, which contributes to the irreversible damages to proteins, lipids and dominantly DNA, leading to mutations and cell death [9].</p>
<p>Depending on the concentration of individual ROS species and the location of ROS products, ROS play a dual role during tumorigenesis and cancer development [10, 11]. ROS act as double-edged swords, low-dose of ROS induces the activation of cell signaling which is involved in promoting events, whereas high-dose of ROS induces apoptotic signaling to kill the cells. ROS are generated by cell-extracellular matrix (ECM) interaction, growth factors and integrin, and redox signaling plays an essential role in anchorage-dependent growth of non-transformed cells [12, 13]. Cancer cells are different from normal cells by constitutively activating growth factor pathways to sustain cell proliferation and growth. This renders cancer cells to take up abundant nutrients, exhibit survival stress and continuous proliferation, leading to abundant ROS production due to the hyper-metabolism from mitochondria, endoplasmic reticulum and the activation of NADPH oxidases [14]. Elevated rate of ROS generation is one of the characteristics of cancer cells, which promotes many aspects of tumor progression [13]. To maintain the delicate balance of intracellular ROS levels required for cancer cell function, tumor cells display an adaptive response to oxidative stress by expressing increased levels of antioxidant proteins for ROS detoxification [15]. Under intrinsic metabolic oxidative stress condition, excessive ROS production induces damage to cellular proteins, lipids, and DNA to promote cancer malignancy [16, 17]. On the other hand, high level of ROS or their products generated from radiation and chemotherapy exerts anti-tumorigenic function to trigger apoptotic process [18]. The mechanisms of adaptation to high-dose ROS generation have in fact contributed to resistance to cancer therapy, and the interruption of these mechanisms will increase ROS-mediated cancer cell apoptosis [19]. Therefore, ROS influence signaling pathways that are critical for determining beneficial or detrimental outcomes, and the modulators of redox signaling pathways to prevent early events in tumor development or to promote ROS-induced apoptotic signaling are potential targets in cancer therapy.</p>
<p><strong>2. THE SIGNALING CASCADES INDUCED BY ROS IN PROMOTING CANCER DEVELOPMENT</strong></p>
<p>ROS cause DNA damage, gene modification and further carcinogenesis through both genotoxic and non-genotoxic effects [20‒22]. The genotoxic effects of ROS usually occur in a dose-dependent manner, leading to point mutations [20], deletions and chromosomal translocations [17]. In this case, ROS contribute to the initiation of carcinogenesis by directly attacking DNA strands, as well as generating the breakdown products of lipid peroxidation to implement mutagenesis. Meanwhile, endogenous ROS via the non-genotoxic effects are mainly involved in tumorigenesis and metastasis [14, 22]. Tumor metastasis formation is a multi-step process where tumor cells already show additional genetic alterations or mutations that allow primary tumor cell detachment from surroundings, invasion and growth at distant site [23]. ROS act as second messengers to affect tumor metastasis through modulating signal transduction pathways to regulate downstream molecules which are important for cancer cell growth, survival, invasion and angiogenesis [14, 22].</p>
<p><strong>2.1. Regulation of Src Kinases by ROS</strong></p>
<p>Src is the prototypic member of a family of non-receptor membrane-associated tyrosine kinases (Src family of protein tyrosine kinases, or SFKs), which are redox-regulated proteins and play important roles in carcinogenesis [24, 25]. The increased ROS cause oxidation-dependent Src activation and recruitment of Src-associated proteins into the signal transduction complex. After contact with ECM, Src displays a slight activation during focal adhesion formation in early phase, and a strong activation associated with ROS production, cell spreading, and integrin-elicited kinase oxidation in late phase [26]. The activation of Src kinases can not only alter ECM components via the activation of extracellular proteases, but also promote tumor cell growth and migration through induction of sustained phosphatidylinositol 3-kinase (PI3K), protein kinase C (PKC) and extracellular-regulated kinase (ERK) activation (<strong>Figure 1</strong>). For example, it has been demonstrated that ROS activated ERK1/2 affects the gene expression of integrins [27, 28], the essential receptors of ECM proteins, as well as decreases the gene expression of E-cadherin in a PKC-dependent manner, leading to the remodel of surrounding tissues and thereby the promotion of epithelial mesenchymal transition (EMT). Src induces EMT through phosphorylation, degradation of E-cadherin [29], and upregulation of mesenchymal markers vimentin and N-cadherin [30]. Redox sensitive Src, which is recruited to and activated in cell-ECM adhesion, plays a key role in the resistance to apoptosis induced by ECM detachment, a phenomenon termed anoikis. It has been reported that transiently increased Src activity triggers PI3K and ERK survival signal to protect epithelial cells from anoikis [27, 30]. Src also transactivates epidermal growth factor receptor (EGFR) and receptor tyrosine kinases (RTKs) signaling to promote carcinogenesis and tumor metastasis. Recent studies also confirmed that mitochondrial DNA mutations generated by ROS enhance the breast cancer metastasis via increased transcription of hypoxia inducible factor 1 (HIF-1α) and the activation of PKC pathways [23]. HIF-1 is a heterodimeric transcription factor composed of two subunits: HIF-1a and HIF-1b. HIF-1b protein is constitutively expressed, whereas HIF-1a expression is induced in human cells by hypoxia, growth factors, and oncogenes. HIF-1a subunit is a rate-limiting factor for HIF-1 activity. HIF-1 activation is important for tumorigenesis and angiogenesis, and HIF-1a expression is frequently increased in many human cancers and is also associated with survival and angiogenesis. In addition to playing a vital role in microenvironment adaption, tumor growth, metastasis and drug resistance in cancer cells, HIF-1a also functions as an important pro-angiogenic factor by regulating its target genes, among which vascular endothelial growth factor (VEGF) has the strongest angiogenic effect in tumor angiogenesis [31, 32]. Our extensive previous studies have shown that PI3K/AKT/HIF-1/VEGF and MAPK/ERK/HIF-1/VEGF pathways are critical for tumor growth and angiogenesis [23, 31, 33, 34]. Therefore, Src redox regulation plays a key role in mediating tumor progression, cell survival and anoikis, receptor cross talk, and angiogenesis.</p>
<p><a href="wp-content/uploads/2017/06/figure-1-1.png"><img class="alignnone size-medium wp-image-1381" src="wp-content/uploads/2017/06/figure-1-1-261x300.png" alt="" width="261" height="300" srcset="http://www.aimsci.com/ros/html/wp-content/uploads/2017/06/figure-1-1-261x300.png 261w, http://www.aimsci.com/ros/html/wp-content/uploads/2017/06/figure-1-1-768x882.png 768w, http://www.aimsci.com/ros/html/wp-content/uploads/2017/06/figure-1-1-892x1024.png 892w, http://www.aimsci.com/ros/html/wp-content/uploads/2017/06/figure-1-1-1080x1240.png 1080w, http://www.aimsci.com/ros/html/wp-content/uploads/2017/06/figure-1-1.png 1256w" sizes="(max-width: 261px) 100vw, 261px" /></a></p>
<p><strong>FIGURE 1.</strong> <strong>The ROS-regulated signaling in tumor metastasis</strong>. ROS can be generated via NADPH oxidases or by electron leak in mitochondria. The excessive intracellular ROS in cancer cells can activate Src/PKC, PI3K/AKT and Ras/MAPKs pathways to affect many transcription factors such as NF-kB, HIF-1, AP-1, p53 and STAT3 that contribute to cancer metastasis by promoting cell growth, survival, invasion and angiogenesis by controlling their target genes and downstream effectors. ROS also directly activate NF-kB signaling for cancer development.</p>
<p><strong>2.2. Regulation of PI3K/AKT Pathway by ROS</strong></p>
<p>The PI3K/AKT pathway is involved in many critical cellular functions including protein synthesis, cell cycle progression, proliferation, anti-apoptosis, invasion, autophagy, angiogenesis and drug resistance in response to the stimulation of growth factors such as VEGF, epidermal growth factor (EGF) and platelet-derived growth factor (PDGF), hormones such as prostaglandin (PGE2), and cytokines such as IL-6 and IL-8 [35‒37]. Once activated by the binding of growth factor to its receptor(s), PI3K catalyzes the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3), which is a second messenger, and recruits and activates proteins that contain the pleckstrin homology (PH) domain such as AKT, subsequently promotes the activation and transcription of the downstream targets including mTOR/p70S6K1, GSK3, FOXO, p53, nuclear factor κ-B (NF-kB) and HIF-1 [32, 37, 38]. ROS directly activate PI3K to amplify its downstream signaling, or indirectly activate PI3K by inactivating phosphatase and tensin homolog deleted on chromosome 10 (PTEN), which hydrolyzes the 3’ phosphate on PIP3 to generate PIP2 and negatively regulates PIP3 mediated signaling pathways [39, 40]. In addition, ROS is able to promote the phosphorylation by casein kinase II of PTEN, which urges PTEN to enter the proteolytic degradation pathway [40, 41].</p>
<p><strong>2.3. Regulation of Mitogen-Activated Protein Kinases (MAPKs) Pathway by ROS</strong></p>
<p>The MAPKs family consists of ERK1/2, the c-Jun N-terminal kinase (JNK), the p38 MAPK and the big MAP kinase 1 (BMK1/ERK5), which are the major and important intracellular signal transduction pathways in mediating various cellular processes such as cell growth, differentiation, development, cell cycle, survival and cell death [42, 43]. The MAPKs transfer intracellular signals from the cell membrane to the nucleus and are activated in response to a wide range of stimuli such as growth factors (EGF and PDGF), cytokines (IL-1b and TNF-a) and environmental stress (particularly, oxidative stress). ROS have been shown to activate the receptors of EGF and PDGF without corresponding ligands, which stimulates Ras and subsequently activates MAPKs pathway [25]. Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) treatment leads to the generation of inositol trisphosphate (IP3) and diacylglycerol (DAG) by phospholipase C phosphorylation and activation. IP3 increases the intracellular calcium to mediate ERK activation, whereas DAG and increased intracellular calcium activate PKC, leading to Ras and Raf activation [44]. In addition, oxidative stress directly or indirectly affects MAP kinase kinase kinase (MEKK) and subsequently activates p38 and JNK pathways [45]. MAPK cascades are important to cancer progression, and increased level of ROS usually enhances MAPK activities that eventually promote tumor metastasis by promoting EMT and cell migration [46]. For example, ROS stimulate EMT in normal human epidermal keratinocytes via ERK1/2 and JNK activation and transforming growth factor β (TGF-b) secretion. Treatment of highly metastatic breast cancer cells with ROS scavengers or inhibitors that target ERK1/2 or its upstream kinase mitogen-activated protein kinase kinase (MEK) attenuates cell migration and invasion [47]. In addition, the research of our lab and others has demonstrated that ROS activated PI3K/AKT and MAPK/ERK pathways play important roles in regulating tumorigenesis, angiogenesis, and metastasis.</p>
<p><strong>2.4. Regulation of Nuclear Factor κ-B (NF-κB) Pathway by ROS</strong></p>
<p>The transcription factor NF-κB is crucial in mediating a series of cellular processes including cellular adhesion, differentiation, proliferation, senescence, apoptosis, immune and inflammatory responses. The NF-κB family members include Rel (c-Rel), RelA (p65), RelB, p50/p105 (NF-κB1), and p52/p100 (NF-κB2). In physiological conditions, NF-κB binds to inhibitors of NF-κB (IκBs) and is sequestered in the cytoplasm. Upon stimulation, IκB kinase (IKK) complexes including IKKα, IKKβ, and NF-κB essential modulator (NEMO, also called IKKγ) are rapidly activated, leading to phosphorylation and proteasome-mediated degradation of IκBs, and the free NF-κB translocates into the nucleus, binds to its consensus sequence, and induces transcription of its target genes [48]. Interestingly, ROS can both positively and negatively regulate NF-κB cascade. Oxidative stress has the potential to activate NF-κB in the early phase, whereas oxidative stress also inhibits basal or inducible activation of NF-κB in the late phase. Accumulating evidence has demonstrated that ROS activates NF-κB pathway by various manners. Typically, ROS induce activation of NF-κB cascade mainly through stimulating the phosphorylation of IκBα. H<sub>2</sub>O<sub>2</sub> treatment affects the phosphorylation of IκBα, leading to the subsequent degradation of IκBα and activation of NF-κB pathway [49, 50]. Moreover, IKK and its kinases upstream MEKK1 are also the primary targets for ROS, and ROS cause the inactivation of MEKK1 and IKKβ through S-glutathionylation to influence NF-κB activity [51, 52]. ROS also disturb IκB ubiquitination and degradation, therefore activating NF-κB via the inactivation of Ubc12 [48]. Finally, ROS activate NF-κB inducing kinase (NIK), the upstream kinase in the noncanonical NF-κB pathway, through inhibition of phosphatases and oxidation of cysteine residues.</p>
<p>The activation of Src/PKC, PI3K/AKT and Ras/MAPKs pathways by endogenous ROS in cancer cells results in the changes of transcription factors such as induction of NF-κB, HIF-1a, AP-1 and STAT3, and inhibition of tumor suppressor p53. As mentioned above, ROS also directly activate NF-κB which has been demonstrated as a key regulator in cancer development by modulating metastasis-associated genes including matrix metalloproteinases (MMPs) [53, 54]. AP-1 induces the expression of genes that function as invasion effectors including MMP9, CD44 and EGFR [55], and represses other genes that function as invasion suppressors such as TSC-36, fibronectin and PCDHGC3 [56]. STAT3 is constitutively activated in many different types of cancer and regulates the expression of numerous oncogenic genes controlling the growth and metastasis of tumor cells [57]. The activated redox-sensitive signaling cascades and related transcription factors promote cancer metastasis by inducing cell growth, survival, invasion and angiogenesis (<strong>Figure 1</strong>).</p>
<p><strong>3. THE INTERPLAY</strong> <strong>OF </strong><strong>ROS</strong><strong> AND</strong><strong> MICRORNAS (MIRNAS)</strong> <strong>IN TUMOR METASTASIS</strong></p>
<p>miRNAs are a group of small endogenous (usually 18‒25 nucleotide-long) noncoding, single stranded RNA species that normally bind to the 3′-untranslated region (UTR) and regulate gene expression through hybridizing to their target messenger RNAs (mRNAs) in a sequence-specific manner, typically leading to mRNA cleavage or suppression of its translation. miRNA expression can be altered by several mechanisms including chromosomal abnormalities, epigenetic changes and oxidative stress.</p>
<p>Compared to normal cells, cancer cells always have a greater capacity to adapt to a hostile and hypoxic environment for survival, which contributes to their malignant and aggressive behavior [10, 58]. This adaptation is controlled by many factors, including the transcriptional and post-transcriptional changes in gene expression in cells [12, 22, 59]. As mentioned, a variety of human genes are responsive to ROS at their transcriptional levels during tumor metastasis. The global microRNA profiling analysis revealed that exposure to hydrogen peroxide caused changes of various microRNA contents [60, 61], suggesting that these ROS-sensitive miRNAs may play important roles in cells, particularly in cancer cells in response to oxidative stress. Up to date, increasing evidence has demonstrated that some miRNAs are redox sensitive and respond to the aberrant cellular oxygen levels, and these ROS-associated miRNAs specifically regulate gene transcription under the oxidative stress. On the other hand, miRNAs are also reported to target mitochondrial protective proteins and antioxidative enzymes to modulate ROS production [62, 63]. In this review, we will focus on ROS-regulated miRNAs in mediating tumorigenesis and cancer development (<strong>Table 1</strong>). All the references related to the targets of these miRNAs are listed in Supplemental Table 1.</p>
<table width="624">
<tbody>
<tr>
<td colspan="4" width="624"><strong>TABLE 1. miRNAs regulated by ROS and their targets in cancer development</strong></td>
</tr>
<tr>
<td width="73"><strong>Name </strong></td>
<td width="71"><strong>Response to ROS </strong></td>
<td width="249"><strong>Targets</strong></td>
<td width="231"><strong>Effect in Cancer </strong></td>
</tr>
<tr>
<td width="73">miR-21</td>
<td width="71"><strong>↑</strong></td>
<td width="249">PTEN, PDCD4, TLR-4, MYD88, CXCL10</td>
<td width="231">Apoptosis, tumorigenesis and cancer development, immune response to cancer cells, therapeutic resistance</td>
</tr>
<tr>
<td width="73">miR-23</td>
<td width="71"><strong>↑</strong></td>
<td width="249">BCL2, SMAD3, Keap-1</td>
<td width="231">Apoptosis, migration, invasion, response to oxidative stress</td>
</tr>
<tr>
<td width="73">miR-210</td>
<td width="71"><strong>↑</strong></td>
<td width="249">E2F3, MNT, Cdc25b, Ccnf, EFNA3, Ptp1b, BCL2, COX10, SDHD</td>
<td width="231">Cell cycle, apoptosis, mitochondrial metabolism, DNA damage, angiogenesis, metastasis</td>
</tr>
<tr>
<td width="73">miR-200</td>
<td width="71"><strong>↑</strong></td>
<td width="249">VEGF, IL8, CXCL1, ZEB1, ZEB2, CDH, MMP3, FN1, FAP1</td>
<td width="231">Tumor growth, angiogenesis, migration, invasion, metastasis and therapeutic resistance</td>
</tr>
<tr>
<td width="73">miR-25</td>
<td width="71"><strong>↑</strong></td>
<td width="249">PTEN, CCNE1, CDKN1C, MOAP1, FBXW7, RECK, CDC42, Bim, cyclin E2</td>
<td width="231">Cell cycle, apoptosis, proliferation, metastasis</td>
</tr>
<tr>
<td width="73">miR-155</td>
<td width="71"><strong>↑</strong></td>
<td width="249">FADD, BCL2, FOXO3a, TP53INP1, RHOA</td>
<td width="231">Apoptosis, EMT, proliferation, migration, invasion, metastasis, immune response, therapeutic resistance</td>
</tr>
<tr>
<td width="73">miR-125b</td>
<td width="71"><strong>↓</strong></td>
<td width="249">ERBB3, cadherin, MMP13, c-Jun, Mcl-1, BCL2, IL-6R, SMAD, MAPK2K7,</td>
<td width="231">Cell proliferation, apoptosis, invasion, EMT, angiogenesis, metastasis, therapeutic resistance</td>
</tr>
<tr>
<td width="73">miR-199a</td>
<td width="71"><strong>↓</strong></td>
<td width="249">ERBB2, ERBB3, IKKB, DDR1, CD44, GRP78, ApoE, HIF-1α, COX-2, SNAI1, N-cadherin, FZD7, FZD6, Bcam, Wnt7a, Podxl, HK2, PKM2, MAP3K11, CCR7, Beclin1</td>
<td width="231">Cell proliferation, invasion, angiogenesis, glycolysis, metastasis, therapeutic resistance</td>
</tr>
<tr>
<td width="73">miR-192</td>
<td width="71"><strong>↓</strong></td>
<td width="249">TCF7, SERPINE1, EGR1, HOXB9, BCL2, ZEB2, VEGFA, RB1, ERCC3, ERCC4</td>
<td width="231">Angiogenesis, proliferation, apoptosis, DNA repair, metastasis, therapeutic resistance</td>
</tr>
<tr>
<td width="73">miR-124</td>
<td width="71"><strong>↓</strong></td>
<td width="249">R-Ras, N-Ras, CDK4, PI3KCA, AKT2, ROCK1, Slug, SNAI2, STAT3, ZEB1, EZH2, Src, DNMT3B, DNMT1</td>
<td width="231">Cell cycle, apoptosis, angiogenesis, cell growth, migration, invasion, metastasis, EMT, DNA methylation, therapeutic resistance</td>
</tr>
<tr>
<td width="73">miR-34a</td>
<td width="71"><strong>↓</strong></td>
<td width="249">CD44, CDK4, CDK6, E2F3, Cyclin E2, BCL2, Myc, c-Met, Notch-1, Notch-2, SIRT1, DLL1</td>
<td width="231">Cell cycle, apoptosis, EMT, metastasis, cancer stem cell phenotype, therapeutic resistance</td>
</tr>
<tr>
<td width="73">let-7</td>
<td width="71"><strong>↓</strong></td>
<td width="249">Bach1, c-Myc, RAS, HMGA1, HMGA2, IL6, TLR4, CCND2</td>
<td width="231">Angiogenesis, proliferation, apoptosis, EMT, metastasis, response to oxidative stress</td>
</tr>
</tbody>
</table>
<p><strong>3.1. ROS-Upregulated miRNAs in Carcinogenesis and Cancer Development </strong></p>
<p>Human cancers display an aberrant expression profile of miRNAs which either act as oncogenic molecules (e.g., miR-21) or tumor-suppressors (e.g., miR-34a), and some of these miRNAs are redox sensitive [60, 64]. Among all the ROS-upregulated miRNAs, miR-21 and miR-155 are well characterized as oncomiRs. For example, ROS-dependent activation of miR-21-programmed cell death 4 protein (PDCD4) signaling mediates arsenic- and chromium-induced malignant transformation of human lung bronchial epithelial cell [65, 66]. PDCD4 is a suppressor of tumorigenesis, tumor progression, and invasion by interacting with translation initiation factors eIF4A and eIF4G to inhibit translation in an mRNA-specific manner, which leads to inhibition of pro-oncogenic factors [67]. A recent study also showed that miR-21 affects toll-like receptor (TLR) pathway by directly targeting TLR-4, myeloid differentiation primary response protein (MYD88) and chemokine CXCL10 [68]. MYD88 is a co-activator of TLR4 signaling for the activation of transcription factors and production of pro-inflammatory cytokines. It has been reported that TLR4 is required for protective immune response and killing of cancer cells [68]. CXCL10 mediates its effects to modulate innate and adaptive immune response by activating T lymphocytes, NK cells, inflammatory dentritic cells, most macrophages and B cells. In addition to the targets above, miR-21 also targets some other tumor suppressor genes such as tissue inhibitor of metalloproteinase 3, tropomyosin 1, ras homolog gene family member B and maspin to promote cancer development [69]. On the other hand, miR-21 also targets SOD3 and down-regulates SOD2 by targeting TNF-a, thus forming a feedback loop to modulate the levels of ROS generation [63]. Thus, these findings clearly suggest that miR-21 has a strict functional interplay with ROS during tumor development.</p>
<p>A recent study has shown that H<sub>2</sub>O<sub>2</sub> scavenger catalase treatment significantly decreases miR-155 expression, demonstrating that miR-155 can be regulated by ROS [70]. miR-155 has been considered to act as an oncogene or a tumor suppressor, depending on tumor system. MiR-155 has been strongly implicated in promoting cancer development of various solid tumors including breast, lung, liver cancers, lymphoma and leukemia since its discovery [71]. A lot of direct targets of miR-155 have been verified. A mini-review by Mattiske S et al. published in 2012 has shown a total of 147 validated miR-155 target genes were identified from the literature in the context of breast cancer [72], indicating the complex effect of miR-155. For instance, oncogenic miR-155 is involved in mediating apoptosis, EMT, cell proliferation, migration, invasion and metastasis by targeting BCL2, FOXO3a, and RhoA (Table 1). However, several studies have shown the tumor suppressor effect of miR-155 [73, 74]. miR-155 deletion mice show a greater number of polyps/adenomas, a higher grade of epithelial dysplasia and a decrease in survival with activation of the TGF-b/SMAD pathway, which is correlated with the increased tumorigenesis using a chemically induced (azoxymethane-dextran sulfate sodium) mouse model of colitis-associated colon cancer, suggesting that careful evaluation of the role of miR-155 in tumorigenesis is necessary prior to any consideration of its potential as a biomarker and/or therapeutic target [75].</p>
<p>Some other miRNAs are also upregulated upon ROS stimulation, including miR-210, miR-200 family members (e.g., miR-141, miR-200a/200b/200c), miR-23 and miR-25. These miRNAs exhibit their role in regulating cell growth, angiogenesis, migration, invasion, cell cycle, apoptosis, EMT, tumor metastasis and drug resistance through targeting their targets, suggesting the important role of oxidative stress-upregulated miRNAs in cancer development (<strong>Table 1</strong>).</p>
<p><strong>3.2. ROS-Downregulated miRNAs in Carcinogenesis and Cancer Development  </strong></p>
<p>miR-34a is a member of the miR-34 family with two other members: miR-34b and miR-34c. It is identified as one of the p53-regulated miRNAs to induce a G1 cell cycle arrest, senescence and apoptosis in response to DNA damage [76, 77]. It has been recently reported that H<sub>2</sub>O<sub>2</sub> promotes miR-34a induction, which is associated with PI3Ka activation and PTEN reduction [78]. miR-34 is an important tumor suppressor in inducing cell cycle arrest, apoptosis, senescence, suppression of EMT and cell proliferation of cancer stem cells [79, 80]. miR-34a targets many oncogenes and cancer stem cell markers including CD44, cyclin-dependent kinases 4, 6 (CDK4, CDK6), Cyclin E2, BCL2, Myc, c-Met, Notch-1, Notch-2, Sirtuin SIRT1 and Delta-like1 (DLL1) to induce tumor suppression by inhibiting cancer regeneration, migration and metastasis (<strong>Table 1</strong>). Other p53-regulated miRNAs, let-7a and let-7b, can also be downregulated upon H<sub>2</sub>O<sub>2</sub> treatment in colon cancer cells in a p53-dependent manner [81]. H<sub>2</sub>O<sub>2</sub> treatment also decreases let-7g expression in gastric cancer cells, suggesting that these let-7 family members are redox sensitive [82]. Let-7 family is composed of let-7a/b/c/d/e/f/g/i and miR-98. Let-7 miRNAs were originally discovered to play crucial roles in the temporal regulation of <em>Caenorhabditis elegans</em> and the maintenance of normal differentiation and development of living organisms [83, 84]. The evidence for the tumor suppressor role of let-7 in cancer came from early research showing that overexpression of let-7 inhibited colon cancer cell proliferation [85], and let-7 miRNAs in human lung cancers are reduced, which is associated with a shortened postoperative survival [86]. In 2005, the 3′-UTRs of the human RAS genes containing multiple let-7 complementary sites (LCSs) were found to be regulated by let-7 miRNA family [87]. Since then, many oncogenes have been identified as direct targets of let-7, including c-Myc, high mobility group AT-hook 1, 2 (HMGA1, HMGA2), IL6, TLR4, central compartment node dissection 2 (CCND2) (<strong>Table 1</strong>), demonstrating that let-7 miRNA family is involved in inhibiting oncogenesis through regulating cell apoptosis, angiogenesis, malignant transformation, EMT and tumor progression. In addition, let-7 also targets Bach1 to enhance heme oxygenase-1 and attenuates oxidant injury in human hepatocytes [88].</p>
<p>A recent publication indicates that low concentration of H<sub>2</sub>O<sub>2</sub> treatment decreases the expression levels of miR-124 in a dose-dependent manner [89]. Growing evidence has demonstrated that miR-124 acts as a tumor suppressor. For example, miR-124 is involved in regulating tumor cell proliferation, migration, radiosensitivity and drug resistance by targeting some oncogenic molecules such as R-Ras, N-Ras, CDK4, PI3KCA, AKT2, Rho-associated kinase1 (ROCK1), STAT3, Src, and CD164 (<strong>Table 1</strong>). More importantly, some well-known oncogenes such as Slug, Snai2 and zinc finger E box binding homeobox 1 (ZEB1) which are EMT-associate genes, are direct targets of miR-124 (<strong>Table 1</strong>). Finally, miR-124 also targets DNA methyltransferases 3B (DNMT3B) and DNMT1, the key enzymes in regulating DNA methylation [90]. Another ROS-decreased miRNA is miR-192 since mouse liver hepatoma cells Hepa 1-6 show significant decrease on miR-192 expression upon H<sub>2</sub>O<sub>2 </sub>treatment [91]. miR-192 targets many genes such as T-cell specific transcription factor (TCF7), plasminogen activator inhibitor-1 (PAI-1) gene (SERPINE1), EGR1, BCL2, ZEB2, VEGFA, retinoblastoma (Rb1), DNA excision repair cross complementing gene (ERCC3, and ERCC4), thereby mediating cell proliferation, apoptosis, DNA repair, tumor angiogenesis, metastasis and therapeutic resistance (<strong>Table 1</strong>).</p>
<p>Our previous study has identified that miR-199a and miR-125b are downregulated by ROS generation. Furthermore, ERBB2 and ERBB3 are direct targets of miR-199a, whereas ERBB3 is a direct target of miR-125b. ROS inhibit miR-199a and miR-125b expression through increasing the promoter methylation of these two miRNAs by DNMT1. Meanwhile, overexpression of miR-199a and miR-125b is associated with the decrease of HIF-1α and VEGF expression that regulates tumor angiogenesis [92, 93], suggesting that redox-sensitive miR-199a and miR-125b act as tumor suppressors in ovarian cancer development. In addition to ERBB2 and ERBB3, it is known that miR-199a targets IKKB, discoidin domain receptor 1 (DDR1), apolipoprotein E (ApoE), the heat shock factor DNAJA4, SNAI1, N-cadherin, Frizzled type 7 receptor (FZD7), FZD6, Bcam, Wnt7a, Podxl, hexokinase 2 (HK2), pyruvate kinase M2 (PKM2), mitogen-activated protein kinase kinase kinase 11 (MAP3K11), chemokine receptor 7 (CCR7), Beclin1, to mediate cell proliferation, angiogenesis, EMT, glycolysis, metastasis, and therapeutic resistance (<strong>Table 1</strong>).</p>
<p>The role of miR-125b in carcinogenesis is controversial. miR-125b acts as a tumor suppressor to suppress cell malignant transformation, cell proliferation, invasion, angiogenesis, cancer development and increase therapeutic effect by targeting ERBB3, c-Raf, E2F3, BCL3, mucin 1(MUC1), LIN28B2, ETS1, STAT3, BCL2, AT-rich interactive domain 3B (ARID3B), vascular endothelial (VE)-cadherin, myc-associated zinc finger protein (MAZ), matrix metallopeptidase 13 (MMP13), Mcl-1, BCL-w, IL-6R, sirtuin 7 (SIRT7), MAD1, phosphoinositide 3-kinase catalytic subunit delta (PIK3CD), ENPEP, CK2-a, CCNJ, MEGF-9, ER alpha-1, 2-mannosidase (ERManI), small mothers against decapentaplegic (SMAD2, SMAD3), Interferon regulatory factor 4 (IRF4), and Sphingosine Kinase 1 (SphK1) (<strong>Table 1</strong>). On the other hand, miR-125b is an important oncomiR in hematopoietic malignancies. For example, overexpression of miR-125b is sufficient both to shorten the latency of BCR-ABL-induced leukemia and to independently induce leukemia in a mouse model [94]. The Emu/miR-125b transgenic mice develop lethal B-cell malignancies [95]. Meanwhile, miR-125b also regulates hematopoiesis by targeting Lin28A [96]. miR-125b has also been reported to act as an oncomiR by targeting TP53INP1, Bcl-2 antagonist killer 1 (Bak1), p53, Puma, StAR-related lipid transfer domain containing 13 (STARD13) and Connexin43 to promote tumor cell growth, invasion, cell renewal and resistance to apoptosis (<strong>Table 1</strong>). miR-125b constitutively activates NF-kB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3) [97], and TNFAIP3 and NF-κB inhibitor interacting RAS-like 2 (NKIRAS2), another target of miR-125b, are involved in temozolomide resistance in glioblastomas [98]. Finally, miR-125b functions as a key mediator for Snail-induced stem cell propogation and chemoresistance. Overexpression of Snail dramatically increases the expression of miR-125b through the Snail-activated Wnt/β-catenin/TCF4 axis. Snail confers chemoresistance to taxol by repressing Bak1 through miR-125b upregulation. Moreover, overexpression of miR-125b significantly increases the cancer stem cell population (CD24<sup>&#8211;</sup> CD44<sup>+</sup>), while depletion of miR-125b or rescue of the expression of Bak1 increases the non-stem cell population (CD24<sup>+</sup> CD44<sup>+</sup>) in Snail-overexpressing cells [99]. Overall, miR-125b plays a dual role in tumorigenesis.</p>
<p><strong>4. SUMMARY</strong></p>
<p>The intracellular production of ROS plays an important role in both cancer initiation and development. ROS emerge on the signaling transduction and miRNAs regulation relevant to tumor metastasis. The activation of PI3K/AKT, PKC, Ras/MAPKs cascades and the downstream transcription factors such as NF-κB, HIF-1, AP-1, p53 and STAT3 are involved in promoting tumor metastasis. Moreover, some miRNAs can be upregulated (miR-21, miR-155, miR-23, miR-210, miR-200 and miR-25) or downregulated (miR-125b, miR-199a, miR-192, miR-124, miR-34a and let-7) by ROS generation, which takes part in mediating malignant transformation, cell proliferation, apoptosis, angiogenesis, migration, invasion, metastasis, glycolysis, EMT, cancer stem cell phenotype, immune surveillance, and therapeutic resistance through their direct targets. On the other hand, some miRNAs such as miR-21 and let-7 are also involved in regulating ROS production by targeting their targets SOD3 and Bach1, or by controlling the expression levels of ROS-related enzymes. In this review, we outline the possible roles of these signaling cascades and ROS-regulated miRNAs in mediating tumor metastasis, which may be helpful for providing potential therapeutic targets for cancer treatment in the future.</p>
<p><strong>ACKNOWLEDGMENTS</strong></p>
<p>This work was supported by the United States ACS award of a Research Scholar Grant (Grant No. PSG-16-052-01-NEC).</p>
<p><strong>REFERENCES</strong></p>
<ol>
<li>Goncalves RL, Quinlan CL, Perevoshchikova IV, Hey-Mogensen M, Brand MD. Sites of superoxide and hydrogen peroxide production by muscle mitochondria assessed ex vivo under conditions mimicking rest and exercise. <em>J Biol Chem</em> 2015; 290(1):209‒27. doi: 10.1074/jbc.M114.619072.</li>
<li>Kim HR, Won SJ, Fabian C, Kang MG, Szardenings M, Shin MG. Mitochondrial DNA aberrations and pathophysiological implications in hematopoietic diseases, chronic inflammatory diseases, and cancers. <em>Ann Lab Med</em> 2015; 35(1):1‒14. doi: 10.3343/alm.2015.35.1.1.</li>
<li>Brigelius-Flohe R. Tissue-specific functions of individual glutathione peroxidases. <em>Free Radic Biol Med</em> 1999; 27(9‒10):951‒65.</li>
<li>Handy DE, Loscalzo J. Redox regulation of mitochondrial function. <em>Antioxid Redox Signal</em> 2012; 16(11):1323‒67. doi: 10.1089/ars.2011.4123.</li>
<li>Babior BM. NADPH oxidase: an update. <em>Blood</em> 1999; 93(5):1464‒76.</li>
<li>Patterson C, Ruef J, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C, et al. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin: evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. <em>J Biol Chem</em> 1999; 274(28):19814‒22.</li>
<li>Winterbourn CC, Hampton MB. Thiol chemistry and specificity in redox signaling. <em>Free Radic Biol Med</em> 2008; 45(5):549‒61. doi: 10.1016/j.freeradbiomed.2008.05.004.</li>
<li>Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. <em>Trends Biochem Sci</em> 2003; 28(1):32‒40.</li>
<li>Clayson DB, Mehta R, Iverson F. International Commission for Protection Against Environmental Mutagens and Carcinogens. Oxidative DNA damagez: the effects of certain genotoxic and operationally non-genotoxic carcinogens. <em>Mutat Res</em> 1994; 317(1):25‒42.</li>
<li>Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. <em>Nat Rev Cancer</em> 2011; 11(2):85‒95. doi: 10.1038/nrc2981.</li>
<li>Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. <em>FEBS Lett</em> 1995; 358(1):1‒3.</li>
<li>Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. <em>Curr Biol</em> 2014; 24(10):R453‒62. doi: 10.1016/j.cub.2014.03.034</li>
<li>Mates JM, Segura JA, Alonso FJ, Marquez J. Oxidative stress in apoptosis and cancer: an update. <em>Arch Toxicol</em> 2012; 86(11):1649‒65. doi: 10.1007/s00204-012-0906-3.</li>
<li>Jiang F, Zhang Y, Dusting GJ. NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. <em>Pharmacol Rev</em> 2011; 63(1):218‒42. doi: 10.1124/pr.110.002980.</li>
<li>Droge W. Free radicals in the physiological control of cell function. <em>Physiol Rev</em> 2002; 82(1):47‒95. doi: 10.1152/physrev.00018.2001.</li>
<li>Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. <em>Chem Biol Interact</em> 2006; 160(1):1‒40. doi: 10.1016/j.cbi.2005.12.009.</li>
</ol>
<ol start="17">
<li>Ferro E, Visalli G, La Rosa MA, Civa R, Papa GR, D&#8217;Ascola DG, et al. The role of anaemia in oxidative and genotoxic damage in transfused beta-thalassaemic patients. <em>Hematology</em> 2016:1‒9. doi: 10.1080/10245332.2016.1244034.</li>
<li>Mates JM, Sanchez-Jimenez FM. Role of reactive oxygen species in apoptosis: implications for cancer therapy. <em>Int J Biochem Cell Biol</em> 2000; 32(2):157‒70.</li>
<li>Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. <em>Drug Resist Updat</em> 2004; 7(2):97‒110. doi: 10.1016/j.drup.2004.01.004.</li>
<li>Magdolenova Z, Collins A, Kumar A, Dhawan A, Stone V, Dusinska M. Mechanisms of genotoxicity: a review of in vitro and in vivo studies with engineered nanoparticles. <em>Nanotoxicology</em> 2014; 8(3):233‒78. doi: 10.3109/17435390.2013.773464.</li>
<li>Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. <em>Circ Res</em> 1992; 70(3):593‒9.</li>
<li>Wu WS. The signaling mechanism of ROS in tumor progression. <em>Cancer Metastasis Rev</em> 2006; 25(4):695‒705. doi: 10.1007/s10555-006-9037-8.</li>
<li>Liu LZ, Hu XW, Xia C, He J, Zhou Q, Shi X, et al. Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. <em>Free Radic Biol Med</em> 2006; 41(10):1521‒33. doi: 10.1016/j.freeradbiomed.2006.08.003.</li>
<li>Tatosyan AG, Mizenina OA. Kinases of the Src family: structure and functions. <em>Biochemistry (Mosc)</em> 2000; 65(1):49‒58.</li>
<li>Lei H, Kazlauskas A. Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells. <em>J Biol Chem</em> 2009; 284(10):6329‒36. doi: 10.1074/jbc.M808426200.</li>
<li>Giannoni E, Buricchi F, Raugei G, Ramponi G, Chiarugi P. Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. <em>Mol Cell Biol</em> 2005; 25(15):6391‒403. doi: 10.1128/MCB.25.15.6391-6403.2005.</li>
<li>Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. <em>Curr Opin Cell Biol</em> 2006; 18(5):516‒23. doi: 10.1016/j.ceb.2006.08.011.</li>
<li>Taddei ML, Parri M, Mello T, Catalano A, Levine AD, Raugei G, et al. Integrin-mediated cell adhesion and spreading engage different sources of reactive oxygen species. <em>Antioxid Redox Signal</em> 2007; 9(4):469‒81. doi: 10.1089/ars.2006.1392.</li>
<li>Palacios F, Tushir JS, Fujita Y, D&#8217;Souza-Schorey C. Lysosomal targeting of E-cadherin: a unique mechanism for the down-regulation of cell-cell adhesion during epithelial to mesenchymal transitions. <em>Mol Cell Biol</em> 2005; 25(1):389‒402. doi: 10.1128/MCB.25.1.389-402.2005.</li>
<li>Giannoni E, Chiarugi P. Redox circuitries driving Src regulation. <em>Antioxid Redox Signal</em> 2014; 20(13):2011‒25. doi: 10.1089/ars.2013.5525.</li>
<li>Zhou Q, Liu LZ, Fu B, Hu X, Shi X, Fang J, et al. Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells. <em>Carcinogenesis</em> 2007; 28(1):28‒37. doi: 10.1093/carcin/bgl085.</li>
<li>Papaiahgari S, Zhang Q, Kleeberger SR, Cho HY, Reddy SP. Hyperoxia stimulates an Nrf2-ARE transcriptional response via ROS-EGFR-PI3K-Akt/ERK MAP kinase signaling in pulmonary epithelial cells. <em>Antioxid Redox Signal</em> 2006; 8(1‒2):43‒52. doi: 10.1089/ars.2006.8.43.</li>
<li>Carpenter RL, Jiang Y, Jing Y, He J, Rojanasakul Y, Liu LZ, et al. Arsenite induces cell transformation by reactive oxygen species, AKT, ERK1/2, and p70S6K1. <em>Biochem Biophys Res Commun</em> 2011; 414(3):533‒8. doi: 10.1016/j.bbrc.2011.09.102.</li>
<li>Xia C, Meng Q, Cao Z, Shi X, Jiang BH. Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. <em>J Cell Physiol</em> 2006; 209(1):56‒66. doi: 10.1002/jcp.20707.</li>
<li>Qi S, Xin Y, Guo Y, Diao Y, Kou X, Luo L, et al. Ampelopsin reduces endotoxic inflammation via repressing ROS-mediated activation of PI3K/Akt/NF-kappaB signaling pathways. <em>Int Immunopharmacol</em> 2012; 12(1):278‒87. doi: 10.1016/j.intimp.2011.12.001.</li>
<li>Li ZY, Yang Y, Ming M, Liu B. Mitochondrial ROS generation for regulation of autophagic pathways in cancer. <em>Biochem Biophys Res Commun</em> 2011; 414(1):5‒8. doi: 10.1016/j.bbrc.2011.09.046.</li>
<li>Park KR, Nam D, Yun HM, Lee SG, Jang HJ, Sethi G, et al. beta-Caryophyllene oxide inhibits growth and induces apoptosis through the suppression of PI3K/AKT/mTOR/S6K1 pathways and ROS-mediated MAPKs activation. <em>Cancer Lett</em> 2011; 312(2):178‒88. doi: 10.1016/j.canlet.2011.08.001.</li>
<li>Zhang J, Wang X, Vikash V, Ye Q, Wu D, Liu Y, et al. ROS and ROS-Mediated Cellular Signaling. <em>Oxid Med Cell Longev</em> 2016; 2016:4350965. doi: 10.1155/2016/4350965.</li>
<li>Leslie NR, Downes CP. PTEN: The down side of PI 3-kinase signalling. <em>Cell Signal</em> 2002; 14(4):285‒95.</li>
<li>Leslie NR, Batty IH, Maccario H, Davidson L, Downes CP. Understanding PTEN regulation: PIP2, polarity and protein stability. <em>Oncogene</em> 2008; 27(41):5464‒76. doi: 10.1038/onc.2008.243.</li>
<li>Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT, et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. <em>Nature</em> 2006; 441(7092):518‒22. doi: 10.1038/nature04747.</li>
<li>Khavari TA, Rinn J. Ras/Erk MAPK signaling in epidermal homeostasis and neoplasia. <em>Cell Cycle</em> 2007; 6(23):2928‒31. doi: 10.4161/cc.6.23.4998.</li>
<li>Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. <em>Oncogene</em> 2007; 26(22):3291‒310. doi: 10.1038/sj.onc.1210422.</li>
<li>Li Z, Ji G, Neugebauer V. Mitochondrial reactive oxygen species are activated by mGluR5 through IP3 and activate ERK and PKA to increase excitability of amygdala neurons and pain behavior. <em>J Neurosci</em> 2011; 31(3):1114‒27. doi: 10.1523/JNEUROSCI.5387-10.2011.</li>
<li>Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. <em>Nat Rev Cancer</em> 2009; 9(8):537‒49. doi: 10.1038/nrc2694.</li>
<li>Wu WS, Wu JR, Hu CT. Signal cross talks for sustained MAPK activation and cell migration: the potential role of reactive oxygen species. <em>Cancer Metastasis Rev</em> 2008; 27(2):303‒14. doi: 10.1007/s10555-008-9112-4.</li>
<li>McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. <em>Biochim Biophys Acta</em> 2007; 1773(8):1263‒84. doi: 10.1016/j.bbamcr.2006.10.001.</li>
<li>Nakajima S, Kitamura M. Bidirectional regulation of NF-kappaB by reactive oxygen species: a role of unfolded protein response. <em>Free Radic Biol Med</em> 2013; 65:162‒74. doi: 10.1016/j.freeradbiomed.2013.06.020.</li>
<li>Schoonbroodt S, Ferreira V, Best-Belpomme M, Boelaert JR, Legrand-Poels S, Korner M, et al. Crucial role of the amino-terminal tyrosine residue 42 and the carboxyl-terminal PEST domain of I kappa B alpha in NF-kappa B activation by an oxidative stress. <em>J Immunol</em> 2000; 164(8):4292‒300.</li>
<li>Takada Y, Mukhopadhyay A, Kundu GC, Mahabeleshwar GH, Singh S, Aggarwal BB. Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. <em>J Biol Chem</em> 2003; 278(26):24233‒41. doi: 10.1074/jbc.M212389200.</li>
<li>Reynaert NL, van der Vliet A, Guala AS, McGovern T, Hristova M, Pantano C, et al. Dynamic redox control of NF-kappaB through glutaredoxin-regulated S-glutathionylation of inhibitory kappaB kinase beta. <em>Proc Natl Acad Sci USA</em> 2006; 103(35):13086‒91. doi: 10.1073/pnas.0603290103.</li>
<li>Cross JV, Templeton DJ. Thiol oxidation of cell signaling proteins: controlling an apoptotic equilibrium. <em>J Cell Biochem</em> 2004; 93(1):104‒11. doi: 10.1002/jcb.20202.</li>
<li>Svineng G, Ravuri C, Rikardsen O, Huseby NE, Winberg JO. The role of reactive oxygen species in integrin and matrix metalloproteinase expression and function. <em>Connect Tissue Res</em> 2008; 49(3):197‒202. doi: 10.1080/03008200802143166.</li>
<li>Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. <em>Nature</em> 2005; 436(7047):123‒7. doi: 10.1038/nature03688.</li>
<li>Ozanne BW, Spence HJ, McGarry LC, Hennigan RF. Transcription factors control invasion: AP-1 the first among equals. <em>Oncogene</em> 2007; 26(1):1‒10. doi: 10.1038/sj.onc.1209759.</li>
<li>Johnston IM, Spence HJ, Winnie JN, McGarry L, Vass JK, Meagher L, et al. Regulation of a multigenic invasion programme by the transcription factor, AP-1: re-expression of a down-regulated gene, TSC-36, inhibits invasion. <em>Oncogene</em> 2000; 19(47):5348‒58. doi: 10.1038/sj.onc.1203927.</li>
<li>Chai EZ, Shanmugam MK, Arfuso F, Dharmarajan A, Wang C, Kumar AP, et al. Targeting transcription factor STAT3 for cancer prevention and therapy. <em>Pharmacol Ther</em> 2016; 162:86‒97. doi: 10.1016/j.pharmthera.2015.10.004.</li>
<li>Liou GY, Storz P. Reactive oxygen species in cancer. <em>Free Radic Res</em> 2010; 44(5):479‒96. doi: 10.3109/10715761003667554.</li>
<li>Wang W, Zhang E, Lin C. MicroRNAs in tumor angiogenesis. <em>Life Sci</em> 2015; 136:28‒35. doi: 10.1016/j.lfs.2015.06.025.</li>
<li>Lin Y, Liu X, Cheng Y, Yang J, Huo Y, Zhang C. Involvement of MicroRNAs in hydrogen peroxide-mediated gene regulation and cellular injury response in vascular smooth muscle cells. <em>J Biol Chem</em> 2009; 284(12):7903‒13. doi: 10.1074/jbc.M806920200.</li>
<li>Shilo S, Roy S, Khanna S, Sen CK. Evidence for the involvement of miRNA in redox regulated angiogenic response of human microvascular endothelial cells. <em>Arterioscler Thromb Vasc Biol</em> 2008; 28(3):471‒7. doi: 10.1161/ATVBAHA.107.160655.</li>
<li>Hu Y, Deng H, Xu S, Zhang J. MicroRNAs regulate mitochondrial function in cerebral ischemia-reperfusion injury. <em>Int J Mol Sci</em> 2015; 16(10):24895‒917. doi: 10.3390/ijms161024895.</li>
<li>Zhang X, Ng WL, Wang P, Tian L, Werner E, Wang H, et al. MicroRNA-21 modulates the levels of reactive oxygen species by targeting SOD3 and TNFalpha. <em>Cancer Res</em> 2012; 72(18):4707‒13. doi: 10.1158/0008-5472.CAN-12-0639.</li>
<li>Simone NL, Soule BP, Ly D, Saleh AD, Savage JE, Degraff W, et al. Ionizing radiation-induced oxidative stress alters miRNA expression. <em>PLoS One</em> 2009; 4(7):e6377. doi: 10.1371/journal.pone.0006377.</li>
<li>Pratheeshkumar P, Son YO, Divya SP, Wang L, Zhang Z, Shi X. Oncogenic transformation of human lung bronchial epithelial cells induced by arsenic involves ROS-dependent activation of STAT3-miR-21-PDCD4 mechanism. <em>Sci Rep</em> 2016; 6:37227. doi: 10.1038/srep37227.</li>
<li>Pratheeshkumar P, Son YO, Divya SP, Turcios L, Roy RV, Hitron JA, et al. Hexavalent chromium induces malignant transformation of human lung bronchial epithelial cells via ROS-dependent activation of miR-21-PDCD4 signaling. <em>Oncotarget</em> 2016; 7(32):51193‒210. doi: 10.18632/oncotarget.9967.</li>
<li>Zakowicz H, Yang HS, Stark C, Wlodawer A, Laronde-Leblanc N, Colburn NH. Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI. <em>RNA</em> 2005; 11(3):261‒74. doi: 10.1261/rna.7191905.</li>
<li>Xu Z, Sharma M, Gelman A, Hachem R, Mohanakumar T. Significant role for microRNA-21 affecting toll-like receptor pathway in primary graft dysfunction after human lung transplantation. <em>J Heart Lung Transplant</em> 2016. doi: 10.1016/j.healun.2016.08.028.</li>
<li>Sekar D, Krishnan R, Thirugnanasambantham K, Rajasekaran B, Islam VI, Sekar P. Significance of microRNA 21 in gastric cancer. <em>Clin Res Hepatol Gastroenterol</em> 2016; 40(5):538‒45. doi: 10.1016/j.clinre.2016.02.010.</li>
<li>Wan C, Han R, Liu L, Zhang F, Li F, Xiang M, et al. Role of miR-155 in fluorooctane sulfonate-induced oxidative hepatic damage via the Nrf2-dependent pathway. <em>Toxicol Appl Pharmacol</em> 2016; 295:85‒93. doi: 10.1016/j.taap.2016.01.023.</li>
<li>Higgs G, Slack F. The multiple roles of microRNA-155 in oncogenesis. <em>J Clin Bioinforma</em> 2013; 3(1):17. doi: 10.1186/2043-9113-3-17.</li>
<li>Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. <em>Cancer Epidemiol Biomarkers Prev</em> 2012; 21(8):1236‒43. doi: 10.1158/1055-9965.EPI-12-0173.</li>
<li>He XH, Zhu W, Yuan P, Jiang S, Li D, Zhang HW, et al. miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells. <em>Oncogene</em> 2016; 35(46):6015‒25. doi: 10.1038/onc.2016.132.</li>
<li>Huffaker TB, Hu R, Runtsch MC, Bake E, Chen X, Zhao J, et al. Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. <em>Cell Rep</em> 2012; 2(6):1697‒709. doi: 10.1016/j.celrep.2012.10.025.</li>
<li>Velazquez KT, Enos RT, McClellan JL, Cranford TL, Chatzistamou I, Singh UP, et al. MicroRNA-155 deletion promotes tumorigenesis in the azoxymethane-dextran sulfate sodium model of colon cancer. <em>Am J Physiol Gastrointest Liver Physiol</em> 2016; 310(6):G347‒58. doi: 10.1152/ajpgi.00326.2015.</li>
<li>Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. <em>Mol Cell</em> 2007; 26(5):731‒43. doi: 10.1016/j.molcel.2007.05.017.</li>
<li>He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. <em>Nature</em> 2007; 447(7148):1130‒4. doi: 10.1038/nature05939.</li>
<li>Baker JR, Vuppusetty C, Colley T, Papaioannou AI, Fenwick P, Donnelly L, et al. Oxidative stress dependent microRNA-34a activation via PI3Kalpha reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells. <em>Sci Rep</em> 2016; 6:35871. doi: 10.1038/srep35871.</li>
<li>Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P, et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming. <em>Nat Cell Biol</em> 2011; 13(11):1353‒60. doi: 10.1038/ncb2366.</li>
<li>Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. <em>Nat Med</em> 2011; 17(2):211‒5. doi: 10.1038/nm.2284.</li>
<li>Saleh AD, Savage JE, Cao L, Soule BP, Ly D, DeGraff W, et al. Cellular stress induced alterations in microRNA let-7a and let-7b expression are dependent on p53. <em>PLoS One</em> 2011; 6(10):e24429. doi: 10.1371/journal.pone.0024429.</li>
<li>Hu H, Zhao X, Jin Z, Hou M. Hsa-let-7g miRNA regulates the anti-tumor effects of gastric cancer cells under oxidative stress through the expression of DDR genes. <em>J Toxicol Sci</em> 2015; 40(3):329‒38. doi: 10.2131/jts.40.329.</li>
<li>Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. <em>Nature</em> 2000; 403(6772):901‒6. doi: 10.1038/35002607.</li>
<li>Ito K, Suda T. Metabolic requirements for the maintenance of self-renewing stem cells. <em>Nat Rev Mol Cell Biol</em> 2014; 15(4):243‒56. doi: 10.1038/nrm3772.</li>
<li>Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. <em>Biol Pharm Bull</em> 2006; 29(5):903‒6.</li>
<li>Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. <em>Cancer Res</em> 2004; 64(11):3753‒6. doi: 10.1158/0008-5472.CAN-04-0637.</li>
<li>Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. <em>Cell</em> 2005; 120(5):635‒47. doi: 10.1016/j.cell.2005.01.014.</li>
<li>Hou W, Tian Q, Steuerwald NM, Schrum LW, Bonkovsky HL. The let-7 microRNA enhances heme oxygenase-1 by suppressing Bach1 and attenuates oxidant injury in human hepatocytes. <em>Biochim Biophys Acta</em> 2012; 1819(11‒12):1113‒22. doi: 10.1016/j.bbagrm.2012.06.001.</li>
<li>Feng CZ, Yin JB, Yang JJ, Cao L. Regulatory factor X1 depresses ApoE-dependent Abeta uptake by miRNA-124 in microglial response to oxidative stress. <em>Neuroscience</em> 2016; 344:217‒28. doi: 10.1016/j.neuroscience.2016.12.017.</li>
<li>Chen Z, Liu S, Tian L, Wu M, Ai F, Tang W, et al. miR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1. <em>Oncotarget</em> 2015; 6(35):38139‒50. doi: 10.18632/oncotarget.5709.</li>
<li>Roy S, Benz F, Alder J, Bantel H, Janssen J, Vucur M, et al. Down-regulation of miR-192-5p protects from oxidative stress-induced acute liver injury. <em>Clin Sci (Lond)</em> 2016; 130(14):1197‒207. doi: 10.1042/CS20160216.</li>
<li>He J, Jing Y, Li W, Qian X, Xu Q, Li FS, et al. Roles and mechanism of miR-199a and miR-125b in tumor angiogenesis. <em>PLoS One</em> 2013; 8(2):e56647. doi: 10.1371/journal.pone.0056647.</li>
<li>He J, Xu Q, Jing Y, Agani F, Qian X, Carpenter R, et al. Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA methylation. <em>EMBO Rep</em> 2012; 13(12):1116‒22. doi: 10.1038/embor.2012.162.</li>
<li>Bousquet M, Harris MH, Zhou B, Lodish HF. MicroRNA miR-125b causes leukemia. <em>Proc Natl Acad Sci USA</em> 2010; 107(50):21558‒63. doi: 10.1073/pnas.1016611107.</li>
<li>Enomoto Y, Kitaura J, Hatakeyama K, Watanuki J, Akasaka T, Kato N, et al. Emu/miR-125b transgenic mice develop lethal B-cell malignancies. <em>Leukemia</em> 2011; 25(12):1849‒56. doi: 10.1038/leu.2011.166.</li>
<li>Chaudhuri AA, So AY, Mehta A, Minisandram A, Sinha N, Jonsson VD, et al. Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A. <em>Proc Natl Acad Sci USA</em> 2012; 109(11):4233‒8. doi: 10.1073/pnas.1200677109.</li>
<li>Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RC. MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). <em>Proc Natl Acad Sci USA</em> 2012; 109(20):7865‒70. doi: 10.1073/pnas.1200081109.</li>
<li>Haemmig S, Baumgartner U, Gluck A, Zbinden S, Tschan MP, Kappeler A, et al. miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. <em>Cell Death Dis</em> 2014; 5:e1279. doi: 10.1038/cddis.2014.245.</li>
<li>Liu Z, Liu H, Desai S, Schmitt DC, Zhou M, Khong HT, et al. miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance. <em>J Biol Chem</em> 2013; 288(6):4334‒45. doi: 10.1074/jbc.M112.419168.</li>
</ol>
					</div> <!-- .entry-content -->

				
				</article> <!-- .et_pb_post -->

			

			</div> <!-- #left-area -->

					</div> <!-- #content-area -->
	</div> <!-- .container -->


</div> <!-- #main-content -->


	<span class="et_pb_scroll_top et-pb-icon"></span>


			<footer id="main-footer">
				

		
				<div id="footer-bottom">
					<div class="container clearfix">
				<div id="footer-info">Reactive Oxygen Species ◊ ©2016‒2019 Cell Med Press, AIMSCI Inc. All rights reserved.</div>					</div>	<!-- .container -->
				</div>
			</footer> <!-- #main-footer -->
		</div> <!-- #et-main-area -->


	</div> <!-- #page-container -->

		<script type="text/javascript">
			</script>
	<script type='text/javascript'>
/* <![CDATA[ */
var DIVI = {"item_count":"%d Item","items_count":"%d Items"};
var et_shortcodes_strings = {"previous":"Previous","next":"Next"};
var et_pb_custom = {"ajaxurl":"http:\/\/www.aimsci.com\/ros\/html\/wp-admin\/admin-ajax.php","images_uri":"http://www.aimsci.com/ros/html/wp-content/themes/Divi/images/","builder_images_uri":"http://www.aimsci.com/ros/html/wp-content/themes/Divi/includes/builder/images/","et_frontend_nonce":"8606b18c1a","subscription_failed":"Please, check the fields below to make sure you entered the correct information.","et_ab_log_nonce":"d44b95b2c4","fill_message":"Please, fill in the following fields:","contact_error_message":"Please, fix the following errors:","invalid":"Invalid email","captcha":"Captcha","prev":"Prev","previous":"Previous","next":"Next","wrong_captcha":"You entered the wrong number in captcha.","ignore_waypoints":"no","is_divi_theme_used":"1","widget_search_selector":".widget_search","is_ab_testing_active":"","page_id":"1377","unique_test_id":"","ab_bounce_rate":"5","is_cache_plugin_active":"no","is_shortcode_tracking":"","tinymce_uri":""};
var et_pb_box_shadow_elements = [];
/* ]]> */
</script>
<script type='text/javascript' src='wp-content/themes/Divi/js/custom.min_1e2ae7de.js'></script>
<script type='text/javascript' src='wp-content/themes/Divi/core/admin/js/common_1e2ae7de.js'></script>
<script type='text/javascript' src='wp-includes/js/wp-embed.min_e0220a6d.js'></script>
</body>
</html>
